| 2026-05-21 |
Compass Therapeutics |
Results Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting compasstherapeutics.com ↗
CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies resistant to prior immune checkpoint inhibitors. |
| 2026-01-06 |
Compass Therapeutics |
Results Compass Therapeutics Provides Corporate Update compasstherapeutics.com ↗
In the ongoing Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody), a previously reported third response has now been confirmed in a patient with Hodgkin Lymphoma (HL). |
| 2024-02-28 |
Compass Therapeutics |
Results Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial compasstherapeutics.com ↗
The data highlighted the unique mechanism-of-action of CTX-8371, inducing dual blockade of PD-1 and PDL-1 and cleavage of cell surface PD-1. |
| 2022-04-08 |
Compass Therapeutics |
Results Compass Therapeutics Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting compasstherapeutics.com ↗
|
| 2019-10-24 |
Compass Therapeutics |
Results Compass Therapeutics to Present Preclinical Data on a Novel PD-1/PD-L1 Bispecific Antibody and from its Proprietary Innate Cell Engager Platform at the 2019 SITC Meeting compasstherapeutics.com ↗
|